Supplements

← vista completa

Published on August 1, 2008 | http://doi.org/10.5867/medwave.2008.07.558

Results of an initial intensive dosing regimen with Myfortic ® in de novo transplant

Resultados de un régimen de dosificación inicial intensiva con Myfortic® en trasplantados de novo

Klemens Budde

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Klemens Budde

Departamento de Nefrología, Hospital y Universidad Charité, Berlín, Alemania

Figures

Article has no figures.

Forum

No messages

History

Citation Budde K. Results of an initial intensive dosing regimen with Myfortic ® in de novo transplant. Medwave 2008;8(07):e558 doi: 10.5867/medwave.2008.07.558

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/08/2008

Index

Metrics

Not available at the moment.

Notes

References

  1. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003 Dec 11;349(24):2326-33. | CrossRef | PubMed
  2. Hale MD, Nicholls AJ, Bullingham RE, Hené R, Hoitsma A, Squifflet JP, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998 Dec;64(6):672-83. | CrossRef | PubMed
  3. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996 Apr;28(2):925-9. | PubMed
  4. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation Am J Transplant. 2004 Jul;4(7):1079-83. | CrossRef | PubMed
  5. Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S,et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007 Nov;7(11):2496-503. Epub 2007 Oct 1. | CrossRef | PubMed
  6. van Gelder T, Silva T, de Fijter Hans, Budde K, Kuypers D, Tyden G, et al. A Prospective, Randomised Study Comparing Fixed Dose Vs Concentration Controlled Mmf Regimens for De Novo Patients Following Renal Transplantation (the Fdcc Trial). Transplantation. Jul 2006; 82 (1):343.
  7. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995 May 27;345(8961):1321-5. | PubMed
  8. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999 Jul 27;68(2):261-6. | CrossRef | PubMed
  9. van Hest R, Mathot R, Vulto A, Weimar W, van Gelder T. Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. van Hest R, Ther Drug Monit. 2005 Apr;27(2):163-7. | CrossRef | PubMed
  10. Pallet N, Anglicheau D, Martinez F, Mamzer MF, Legendre C, Thervet E. Comparison of sequential protocol using basiliximab versus antithymocyte globulin with high-dose mycophenolate mofetil in recipients of a kidney graft from an expanded-criteria donor. Transplantation. 2006 Mar 27;81(6):949-52. | CrossRef | PubMed